SOLICITATION NOTICE
A -- PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarker Endpoints, Preclinical Services for Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing - Presolicitation Notice
- Notice Date
- 4/19/2018
- Notice Type
- Presolicitation
- NAICS
- 541714
— Research and Development in Biotechnology (except Nanobiotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions-Treatment and Support Branch, Bldg 244, Room 112, Frederick, Maryland, 21702
- ZIP Code
- 21702
- Solicitation Number
- N01CN77019-18
- Archive Date
- 5/19/2018
- Point of Contact
- Nicole Belanger, Phone: 3016248754, Carrie L. Mills, Phone: 3016241274
- E-Mail Address
-
belangern@mail.nih.gov, carrie.mills@nih.gov
(belangern@mail.nih.gov, carrie.mills@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Attachment 4 of 4- Toxicology/Pharmacology IDIQ Draft Statement of Work Attachment 3 of 4- CGMP IDIQ Draft Statement of Work Attachment 2 of 4- Efficacy IDIQ Draft Statement of Work Attachment 1 of 4- Draft Background & Introduction Presolicitation Notice Please see the attached documents related to the Presolicitation Notice for RFP No. N01CN77019-18 'PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarker Endpoints, Preclinical Services for Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing'.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/FCRF2/N01CN77019-18/listing.html)
- Place of Performance
- Address: Contractor's Facility, United States
- Record
- SN04895013-W 20180421/180419230542-b28ec2e4dbc88c1d39291d626aa0a1e4 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |